Summary
Bristol-Myers Squbb Co. (BMY) reported a strong first quarter for 2017, with total revenues increasing by 12% year-over-year to $4.93 billion. This growth was primarily driven by robust performance in their prioritized brands, Opdivo and Eliquis, which saw significant increases in sales. Net earnings attributable to BMS rose to $1.57 billion, translating to a diluted EPS of $0.94, up from $0.71 in the prior year quarter. The company's operational cash flow improved substantially, turning positive at $861 million compared to a use of cash in the prior year, bolstered by lower income tax payments and a significant litigation settlement related to Keytruda. Key strategic initiatives for the quarter included expanding the collaboration with CytomX for novel therapies and agreeing to out-license compounds to Biogen and Roche, generating substantial upfront payments. The company also continued its disciplined capital allocation, executing accelerated share repurchases totaling $2 billion, funded by a combination of debt and cash. Despite facing ongoing litigation and potential generic competition for established brands, BMY demonstrated solid top-line growth and improved profitability, positioning itself for continued strategic development in its core therapeutic areas.
Financial Highlights
57 data points| Revenue | $4.93B |
| Cost of Revenue | $1.26B |
| Gross Profit | $3.66B |
| R&D Expenses | $1.30B |
| SG&A Expenses | $1.08B |
| Operating Expenses | $2.97B |
| Interest Expense | $45.00M |
| Net Income | $1.57B |
| EPS (Basic) | $0.95 |
| EPS (Diluted) | $0.94 |
| Shares Outstanding (Basic) | 1.66B |
| Shares Outstanding (Diluted) | 1.67B |
Key Highlights
- 1Total Revenues increased 12% year-over-year to $4.93 billion, driven by strong performance of prioritized brands Opdivo and Eliquis.
- 2Net Earnings Attributable to BMS grew to $1.57 billion, resulting in a Diluted EPS of $0.94, an increase from $0.71 in the prior year period.
- 3Operating cash flow turned positive, reaching $861 million, a significant improvement from a negative $228 million in Q1 2016.
- 4The company announced strategic collaborations, including expanding the partnership with CytomX and out-licensing agreements with Biogen and Roche, generating substantial upfront payments.
- 5BMY executed accelerated share repurchases totaling $2 billion, demonstrating a commitment to returning capital to shareholders.
- 6Despite challenges with established brands like the Hepatitis C Franchise seeing a 62% revenue decline, the growth in key products offset these impacts.
- 7Significant one-time events influenced results, including a $481 million payment received from Merck related to a patent litigation settlement for Keytruda.